CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER
Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KINOSHITA, Taisei BUTLER, Thomas PALMER, James T TAN, Heow LAW, Brian JAING, Siyi SOMANATH, Priyanka WONG, Angelina Sau Man HE, Hongyan LU, Daniel LIN, Nan-Horng |
| description | Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4387972A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4387972A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4387972A13</originalsourceid><addsrcrecordid>eNqNj89qwzAMxnPZYWx7Bx8TqA5JSrMdnUTBAtsyqhkNIZQystPYCt077zVmwx5gINC_38cn3Rc_g8zHqK0lj2picYon5WHZ5yj34FiC4bSdbQWdgTCLsOWl2bUwrqkjRyN5OMBs12AwcSsk8dKWUsFS1sAnVtBAEA7ooU5cpR15XlMdKKBkfVI5jCaLm-yRZzho6fmU4BF3SntFIviKcqTeonLok62zVpE31FNkyferaFBFQR0TEPMzg_YDymNx9375uG1Pf_mhUBPGwcB2_Tpvt-vlbfvcvs8Y9u1z99I1um7_gfwCU-VXyA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER</title><source>esp@cenet</source><creator>KINOSHITA, Taisei ; BUTLER, Thomas ; PALMER, James T ; TAN, Heow ; LAW, Brian ; JAING, Siyi ; SOMANATH, Priyanka ; WONG, Angelina Sau Man ; HE, Hongyan ; LU, Daniel ; LIN, Nan-Horng</creator><creatorcontrib>KINOSHITA, Taisei ; BUTLER, Thomas ; PALMER, James T ; TAN, Heow ; LAW, Brian ; JAING, Siyi ; SOMANATH, Priyanka ; WONG, Angelina Sau Man ; HE, Hongyan ; LU, Daniel ; LIN, Nan-Horng</creatorcontrib><description>Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240626&DB=EPODOC&CC=EP&NR=4387972A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25566,76549</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240626&DB=EPODOC&CC=EP&NR=4387972A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KINOSHITA, Taisei</creatorcontrib><creatorcontrib>BUTLER, Thomas</creatorcontrib><creatorcontrib>PALMER, James T</creatorcontrib><creatorcontrib>TAN, Heow</creatorcontrib><creatorcontrib>LAW, Brian</creatorcontrib><creatorcontrib>JAING, Siyi</creatorcontrib><creatorcontrib>SOMANATH, Priyanka</creatorcontrib><creatorcontrib>WONG, Angelina Sau Man</creatorcontrib><creatorcontrib>HE, Hongyan</creatorcontrib><creatorcontrib>LU, Daniel</creatorcontrib><creatorcontrib>LIN, Nan-Horng</creatorcontrib><title>CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER</title><description>Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNj89qwzAMxnPZYWx7Bx8TqA5JSrMdnUTBAtsyqhkNIZQystPYCt077zVmwx5gINC_38cn3Rc_g8zHqK0lj2picYon5WHZ5yj34FiC4bSdbQWdgTCLsOWl2bUwrqkjRyN5OMBs12AwcSsk8dKWUsFS1sAnVtBAEA7ooU5cpR15XlMdKKBkfVI5jCaLm-yRZzho6fmU4BF3SntFIviKcqTeonLok62zVpE31FNkyferaFBFQR0TEPMzg_YDymNx9375uG1Pf_mhUBPGwcB2_Tpvt-vlbfvcvs8Y9u1z99I1um7_gfwCU-VXyA</recordid><startdate>20240626</startdate><enddate>20240626</enddate><creator>KINOSHITA, Taisei</creator><creator>BUTLER, Thomas</creator><creator>PALMER, James T</creator><creator>TAN, Heow</creator><creator>LAW, Brian</creator><creator>JAING, Siyi</creator><creator>SOMANATH, Priyanka</creator><creator>WONG, Angelina Sau Man</creator><creator>HE, Hongyan</creator><creator>LU, Daniel</creator><creator>LIN, Nan-Horng</creator><scope>EVB</scope></search><sort><creationdate>20240626</creationdate><title>CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER</title><author>KINOSHITA, Taisei ; BUTLER, Thomas ; PALMER, James T ; TAN, Heow ; LAW, Brian ; JAING, Siyi ; SOMANATH, Priyanka ; WONG, Angelina Sau Man ; HE, Hongyan ; LU, Daniel ; LIN, Nan-Horng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4387972A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>KINOSHITA, Taisei</creatorcontrib><creatorcontrib>BUTLER, Thomas</creatorcontrib><creatorcontrib>PALMER, James T</creatorcontrib><creatorcontrib>TAN, Heow</creatorcontrib><creatorcontrib>LAW, Brian</creatorcontrib><creatorcontrib>JAING, Siyi</creatorcontrib><creatorcontrib>SOMANATH, Priyanka</creatorcontrib><creatorcontrib>WONG, Angelina Sau Man</creatorcontrib><creatorcontrib>HE, Hongyan</creatorcontrib><creatorcontrib>LU, Daniel</creatorcontrib><creatorcontrib>LIN, Nan-Horng</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KINOSHITA, Taisei</au><au>BUTLER, Thomas</au><au>PALMER, James T</au><au>TAN, Heow</au><au>LAW, Brian</au><au>JAING, Siyi</au><au>SOMANATH, Priyanka</au><au>WONG, Angelina Sau Man</au><au>HE, Hongyan</au><au>LU, Daniel</au><au>LIN, Nan-Horng</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER</title><date>2024-06-26</date><risdate>2024</risdate><abstract>Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP4387972A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | CRYSTALLINE FORM OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, AN IRREVERSIBLE MENIN-MLL INHIBITOR FOR THE TREATMENT OF CANCER |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T09%3A20%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KINOSHITA,%20Taisei&rft.date=2024-06-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4387972A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |